Dalton Pharma Services Invests in Fully Automated Sterile Liquid Filling System

As a part of a $10-million dollar facility and capital expansion, Dalton Pharma Services, a leading North American contract research, development & manufacturing organization, has invested in a fully automated Sterile Liquid Filling System that will become operational in Q1 of 2019. The new fill line allows larger batch sizes (~40 BPM), a broader range of filling volumes, and container closure systems. It also provides nitrogen purging and individual bottle serialization.

This is the next step in Dalton’s continued facility and service improvements to meet its increasing clients’ requirements to shorten lead times and scale up from clinical batches to small scale commercial production.


“The flexibility and aseptic assurance that this new fill-line provides will enable Dalton to extend services beyond the current clinical stage and accelerate the development of clients’ sterile drug products to reach the market, faster,” said Peter Pekos, CEO and President, Dalton Pharma Services.


Dalton Pharma Services is a leading North American cGMP pharmaceutical organization providing integrated drug discovery, development, and manufacturing services. It is FDA registered and Health Canada approved and brings over 30 years of experience to every project. Dalton delivers fully integrated solutions with an emphasis on speed, flexibility, and quality. For more information, www.dalton.com.